KEYTRUDA 25 mg/mL concentrate for solution for infusion, MYCOPHENOLATE MOFETIL, PEMETREXED, INFLIXIMAB, Rilvegostomig, PEMETREXED, CISPLATIN, CARBOPLATIN
D702FC00001
Phase 3 small_molecule active
Quick answer
KEYTRUDA 25 mg/mL concentrate for solution for infusion, MYCOPHENOLATE MOFETIL, PEMETREXED, INFLIXIMAB, Rilvegostomig, PEMETREXED, CISPLATIN, CARBOPLATIN for Metastatic Non-squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1 is a Phase 3 program (small_molecule) at AstraZeneca AB with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AstraZeneca AB
- Indication
- Metastatic Non-squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active